View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 25, 2018

Merus doses first patient in Phase I trial of MCLA-158

Merus has dosed the first patient in a Phase I clinical trial of MCLA-158 to treat patients with solid tumours with an initial focus on metastatic colorectal cancer. 

Merus has dosed the first patient in a Phase I clinical trial of MCLA-158 to treat patients with solid tumours with an initial focus on metastatic colorectal cancer.

The first-in-human trial follows approval of an investigational new drug (IND) application by the US Food and Drug Administration (FDA) for MCLA-158 last month.

This approval has lead the way for Merus to conduct the trial in the US.

Initially, the open-label, multi-centre trial will be carried out across various sites in Europe.

The trial includes two parts, a dose escalation and a dose expansion phase.

The dose escalation part aims to determine the appropriate dose of MCLA-158, while the dose expansion aspect will examine safety and tolerability of the defined dose of MCLA-158 for solid tumours patients.

“We believe MCLA-158 has the potential to address features that limit currently approved colorectal cancer-targeted therapies.”

Both parts will also evaluate the preliminary anti-tumour activity of single-agent MCLA-158.

Merus CEO Ton Logtenberg said: “The commencement of our Phase I clinical trial of MCLA-158 is an important milestone for the advancement of our pipeline of bispecific antibodies obtained from our Biclonics technology platform.

“We believe MCLA-158 has the potential to address features that limit currently approved colorectal cancer-targeted therapies, including issues with off-target toxicity and inability to target tumour stem cells, and thus, potentially treat a broader population of patients more effectively.”

MCLA-158 has been developed to bind to cancer stem cells demonstrating leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptors (EGFR).

Functional review of patient-derived colorectal tumours previously showed that MCLA-158 was more effective at inhibiting tumour growth and promoting apoptosis than cetuximab, an approved targeted therapy comparator for metastatic colorectal cancer.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU